Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies

In patients with primary antibody deficiencies, subcutaneous administration of IgG (SCIG) replacement is effective, safe, well-tolerated, and can be self-administered at home. A new SCIG replacement at 20% concentration (Hizentra(®)) has been developed and has replaced Vivaglobin(®) (SCIG 16%). An o...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রকাশিত:Int J Immunopathol Pharmacol
প্রধান লেখক: Canessa, Clementina, Iacopelli, Jessica, Pecoraro, Antonio, Spadaro, Giuseppe, Matucci, Andrea, Milito, Cinzia, Vultaggio, Alessandra, Agostini, Carlo, Cinetto, Francesco, Danieli, Maria Giovanna, Gambini, Simona, Marasco, Carolina, Trizzino, Antonino, Vacca, Angelo, De Mattia, Domenico, Martire, Baldassarre, Plebani, Alessandro, Di Gioacchino, Mario, Gatta, Alessia, Finocchi, Andrea, Licciardi, Francesco, Martino, Silvana, De Carli, Marco, Moschese, Viviana, Azzari, Chiara
বিন্যাস: Artigo
ভাষা:Inglês
প্রকাশিত: SAGE Publications 2016
বিষয়গুলি:
Letters to the Editor
অনলাইন ব্যবহার করুন:https://ncbi.nlm.nih.gov/pmc/articles/PMC5806788/
https://ncbi.nlm.nih.gov/pubmed/27927705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0394632016681577
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি